Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457437 | 0.90 | TRPV1 (0.39) | TRPA1TRPV1RBP4GRM1SLC6A7 | |
| SCHEMBL5116491 | 0.88 | POLB (0.51) | TRPA1TRPV1POLBGPR119 | |
| SCHEMBL2203441 | 0.86 | GRM1 (0.46) | TRPA1TRPV1RBP4GRM1SLC6A7 | |
| SCHEMBL2203446 | 0.86 | GRM1 (0.46) | TRPA1TRPV1RBP4GRM1SLC6A7 | |
| SCHEMBL1457263 | 0.84 | TRPV1 (0.60) | TRPA1TRPV1 | |
| SCHEMBL12512458 | 0.83 | TRPV1 (0.41) | TRPA1TRPV1RBP4GRM1SLC6A7 | |
| SCHEMBL1457200 | 0.78 | TRPA1 (0.46) | TRPA1TRPV1POLBRBP4 | |
| SCHEMBL5126434 | 0.76 | TRPV1 (0.52) | TRPA1TRPV1POLBGPR119RBP4 | |
| SCHEMBL2209388 | 0.75 | HSD11B1 (0.44) | TRPA1TRPV1GRM1SLC6A7 | |
| SCHEMBL2209392 | 0.75 | HSD11B1 (0.44) | TRPA1TRPV1GRM1SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292625-A1 | Substituted spiro compounds and their use for producing pain-relief medicaments | Grünenthal GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | TRPA1 720/4885TRPV1 675/4885POLB 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.